Refine by
Copd Articles & Analysis
84 news found
Asthma remains a complex and multifactorial disease, with airway hyperresponsiveness to methacholine being a hallmark feature. A recent study by Rojas-Ruiz et al (2025) utilizes SCIREQ’s innovative physioLens (ex vivo) and flexiVent (in vivo) platforms to shed light on the interplay between lung tissue compliance and methacholine response, offering new insights into the mechanisms ...
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
Vitalograph has joined forces with MedM Inc. to further enhance patient respiratory monitoring experience with digital health capabilities. The MedM health monitoring app is paired with Vitalograph’s Asthma-1 BT and Lung Monitor BT Smart devices. The app works as a digital asthma or lung function diary, helping users to better understand and manage their condition. Patient diaries like ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, in Washington. Developed in partnership with Thorasys, the Vitalograph tremoflo® C-100 oscillometer helps to detect the presence of small airway impairment, providing ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are thrilled to receive this investment, which raises Third Pole Therapeutics’ series B financing and commitments to date to over $85M. I am ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to ...
Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, makes breathing difficult for millions of Americans who have been diagnosed with the condition. The Centers for Disease Control and Prevention (CDC) reports that millions more suffer from the respiratory disease, but have not been diagnosed or treated. In Puerto Rico and throughout the rest of the ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast of the presentation will be available ...
We are happy to announce that the #simeox device is now commercially available in Canada. Proud to partner with Novus Medical to help respiratory clinicians improve the life of their patients through access to Simeox. The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, ...
Beyond Air, Inc. (NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is scheduled to participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022, at 8:00AM ET. Interested ...
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed ...
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. This clearance further validates the quality and clinical efficacy of the ...
Fluidda, leader in the field of Functional Respiratory Imaging and developer of the medical device Broncholab®, today announced an exclusive collaboration with Nanopharm, an Aptar Pharma company and a leader in contract research and development services for orally inhaled and nasal drug products (OINDPs). The companies will leverage their respective proprietary technology platforms to help ...
ByFluidda
Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it’s abstract titled “Metabolomic Profiling for the Early Detection of Lung Cancer” has been ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the ...
Six digital health start-ups from five countries have officially become the first cohort of the Edison Accelerator in Canada – a program designed by GE Healthcare and delivered in collaboration with Nex Cubed to accelerate, validate, and scale innovative solutions that address important challenges in the healthcare sector. The companies all focus on applying Artificial Intelligence (AI) to ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 27, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 10, 2022, at 1:00 PM PT / 4:00 PM ET. ...